{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:56:27Z","timestamp":1789480587137,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune Hemolytic anemia (AIHA) a relatively uncommon form of hemolytic anemia, which is characterized by the presence of autoantibodies directed against erythrocyte surface antigens, most frequently of the IgG isotype. A positive Direct Antiglobulin Test (DAT) is a key diagnostic criterion for AIHA. However, when hemolysis involves multiple autoantibodies, the standard DAT (polyspecific, anti-IgG + C3) may fail to detect certain antibodies, potentially delaying appropriate treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases presentation<\/jats:title>\n                    <jats:p>We reported one patient with severe AIHA mediated by IgG and IgA autoantibodies was successfully treated with Multi-drug combination regimens. A 58-year-old female was admitted to the hospital presenting with a history of fatigue, jaundice and soy sauce-colored urine for one day. Upon admission, a complete blood count revealed a critically low hemoglobin level of 41 g\/L and a life-threatening condition. Initially diagnosed with IgG-mediated AIHA via standard DAT, the patient showed suboptimal response to glucocorticoids, intravenous immunoglobulin (IVIG), and transfusion support. Subsequently, through the extended DAT (monospecific, anti-IgA, anti-IgG, anti-IgM, and anti-C3) test results, the patient was diagnosed as severe AIHA mediated by IgG and IgA. Based on extended DAT results, the treatment plan was modified to include combination therapy with dexamethasone, rituximab, cyclosporine, and bortezomib, alongside intensified plasma exchange.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The extended DAT testing is recommended for all patients with clinical and laboratory evidence of acute hemolysis. Early detection helps in avoiding further investigations and provide efficient management. Severe AIHA mediated by multiple autoantibodies requires early intensive combination therapy, including immunosuppressive agents, IVIG and plasma exchange.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1664498","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:46:54Z","timestamp":1762429614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Severe autoimmune hemolytic anemia in an elderly patient caused by warm-reactive IgG and IgA autoantibodies"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenxia","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036053","article-title":"New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children","volume":"96","author":"Aladjidi","year":"2011","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019024","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37297203520.x","article-title":"IgA red cell autoantibodies and autoimmune hemolysis","volume":"37","author":"Sokol","year":"1997","journal-title":"Transfusion"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2022-047","article-title":"Clinical perspectives, immunohematologic insights, and transfusion management in IgA-associated autoimmune hemolytic anemia","volume":"38","author":"Das","year":"2022","journal-title":"Immunohematology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.3.820.820","article-title":"Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases","volume":"69","author":"Liesveld","year":"1987","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10062","article-title":"Autoimmune hemolytic anemia","volume":"69","author":"Gehrs","year":"2002","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2008.00891.x","article-title":"The James Blundell Award Lecture 2007: do we really understand immune red cell destruction","volume":"18","author":"Garratty","year":"2008","journal-title":"Transfus Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20033","article-title":"Comparison of conventional tube test technique and gel microcolumn assay for direct antiglobulin test: a large study","volume":"18","author":"Novaretti","year":"2004","journal-title":"J Clin Lab Anal"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.12.001","article-title":"Autoimmune hemolytic anemia: diagnosis and differential diagnosis","volume":"36","author":"Scheckel","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.5.1000.1000","article-title":"Acquired immune hemolytic anemia associated with IgA erythrocyte coating: investigation of hemolytic mechanisms","volume":"64","author":"Clark","year":"1984","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-740","article-title":"Autoimmune hemolytic anemia due to IgA class autoantibodies","volume":"12","author":"Sokol","year":"1996","journal-title":"Immunohematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276162","article-title":"IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and Fc\u03b1RI","volume":"116","author":"Chadebech","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22932","article-title":"IgA-mediated autoimmune hemolytic anemia in an infant","volume":"56","author":"McGann","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000001765","article-title":"Primary igA-mediated autoimmune hemolytic anemia in an infant successfully treated with rituximab","volume":"42","author":"van den Akker","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21341","article-title":"Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases","volume":"84","author":"Bussone","year":"2009","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12486","article-title":"A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia","volume":"163","author":"Maung","year":"2013","journal-title":"Br J Haematol"},{"key":"B25","first-page":"100","article-title":"Favorable response to cyclosporin A in a patient with steroid resistant autoimmune haemolytic anaemia","volume":"95","author":"Baratta","year":"2004","journal-title":"Recenti Prog Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5152\/tjh.2011.54","article-title":"Management of autoimmune hemolytic anemia in children and adolescents: A single center experience","volume":"28","author":"Sarper","year":"2011","journal-title":"Turk J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2235832","article-title":"Severe autoimmune hemolytic anemia complicating hereditary spherocytosis treated successfully with glucocorticoids and cyclosporine: a case report","volume":"28","author":"Wang","year":"2023","journal-title":"Hematology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27540","article-title":"Rituximab plus bortezomib for relapsed and refractory warm autoimmune hemolytic anemia: A prospective phase 2 trial","volume":"100","author":"Lin","year":"2025","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e28679","DOI":"10.1097\/md.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03976-w","article-title":"Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia","volume":"99","author":"Chen","year":"2020","journal-title":"Ann Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07430.x","article-title":"Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia","volume":"60","author":"Macintyre","year":"1985","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00235.x","article-title":"Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1)","volume":"42","author":"Janvier","year":"2002","journal-title":"Transfusion"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:46:56Z","timestamp":1762429616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1664498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1664498"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1664498","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1664498"}}